Details
| Original language | English |
|---|---|
| Pages (from-to) | 47 |
| Number of pages | 1 |
| Journal | BMC neurology |
| Volume | 9 |
| Publication status | Published - 25 Aug 2009 |
Abstract
Background: The number of individuals at risk for dementia will probably increase in ageing societies as will the array of preventive and therapeutic options, both however within limited economic resources. For economic and medical purposes valid instruments are required to assess disease processes and the efficacy of therapeutic interventions for different forms and stages of illness. In principal, the impact of illness and success of an intervention can be assessed with biomedical variables, e.g. severity of symptoms or frequency of complications of a disease. However, this does not allow clear judgement on clinical relevance or comparison across different diseases. Discussion: Outcome model variables such as quality of life (QoL) or health care resource utilization require the patient to appraise their own well-being or third parties to set preferences. In Alzheimer's disease and other dementias the evaluation process performed by the patient is subject to the disease process itself because over progress of the disease neuroanatomical structures are affected that mediate evaluation processes. Summary: Published research and methodological considerations thus lead to the conclusion that current QoL-instruments, which have been useful in other contexts, are ill-suited and insufficiently validated to play a major role in dementia research, decision making and resource allocation. New models integrating biomedical and outcome variables need to be developed in order to meet the upcoming medical and economic challenges.
ASJC Scopus subject areas
- Medicine(all)
- Clinical Neurology
Cite this
- Standard
- Harvard
- Apa
- Vancouver
- BibTeX
- RIS
In: BMC neurology, Vol. 9, 25.08.2009, p. 47.
Research output: Contribution to journal › Article › Research › peer review
}
TY - JOUR
T1 - Quality of Life as an outcome in Alzheimer's disease and other dementias
T2 - obstacles and goals
AU - Riepe, Matthias W.
AU - Mittendorf, Thomas
AU - Förstl, Hans
AU - Frölich, Lutz
AU - Haupt, Martin
AU - Leidl, Reiner
AU - Vauth, Christoph
AU - von der Schulenburg, Matthias G.
PY - 2009/8/25
Y1 - 2009/8/25
N2 - Background: The number of individuals at risk for dementia will probably increase in ageing societies as will the array of preventive and therapeutic options, both however within limited economic resources. For economic and medical purposes valid instruments are required to assess disease processes and the efficacy of therapeutic interventions for different forms and stages of illness. In principal, the impact of illness and success of an intervention can be assessed with biomedical variables, e.g. severity of symptoms or frequency of complications of a disease. However, this does not allow clear judgement on clinical relevance or comparison across different diseases. Discussion: Outcome model variables such as quality of life (QoL) or health care resource utilization require the patient to appraise their own well-being or third parties to set preferences. In Alzheimer's disease and other dementias the evaluation process performed by the patient is subject to the disease process itself because over progress of the disease neuroanatomical structures are affected that mediate evaluation processes. Summary: Published research and methodological considerations thus lead to the conclusion that current QoL-instruments, which have been useful in other contexts, are ill-suited and insufficiently validated to play a major role in dementia research, decision making and resource allocation. New models integrating biomedical and outcome variables need to be developed in order to meet the upcoming medical and economic challenges.
AB - Background: The number of individuals at risk for dementia will probably increase in ageing societies as will the array of preventive and therapeutic options, both however within limited economic resources. For economic and medical purposes valid instruments are required to assess disease processes and the efficacy of therapeutic interventions for different forms and stages of illness. In principal, the impact of illness and success of an intervention can be assessed with biomedical variables, e.g. severity of symptoms or frequency of complications of a disease. However, this does not allow clear judgement on clinical relevance or comparison across different diseases. Discussion: Outcome model variables such as quality of life (QoL) or health care resource utilization require the patient to appraise their own well-being or third parties to set preferences. In Alzheimer's disease and other dementias the evaluation process performed by the patient is subject to the disease process itself because over progress of the disease neuroanatomical structures are affected that mediate evaluation processes. Summary: Published research and methodological considerations thus lead to the conclusion that current QoL-instruments, which have been useful in other contexts, are ill-suited and insufficiently validated to play a major role in dementia research, decision making and resource allocation. New models integrating biomedical and outcome variables need to be developed in order to meet the upcoming medical and economic challenges.
UR - http://www.scopus.com/inward/record.url?scp=70349562949&partnerID=8YFLogxK
U2 - 10.1186/1471-2377-9-47
DO - 10.1186/1471-2377-9-47
M3 - Article
C2 - 19706186
AN - SCOPUS:70349562949
VL - 9
SP - 47
JO - BMC neurology
JF - BMC neurology
SN - 1471-2377
ER -